Watch More Highlights
Tiffany Richards, PhD, ANP-BC, AOCNP®, of The University of Texas MD Anderson Cancer Center, reviews updated efficacy and safety data for BMS-986393 (CC‑95266), a GPRC5D-targeted autologous chimeric antigen receptor (CAR) T-cell therapy in patients with relapsed/refractory multiple myeloma. This first-in-human study showed a manageable safety profile, along with deep and durable responses, including minimal residual disease negativity (Abstract 219).